Barrett's%20esophagus News

News

Patients at risk for BE worried over EAC but rarely undergoes screening: study

20230425110000

Patients who are prone to Barrett’s esophagus (BE), specifically those belonging to racial and ethnic minorities, express concern about developing esophageal adenocarcinoma (EAC), reveals a study. However, they seldom go through screening and lack awareness of screening recommendations.

Esophagogastric junction biopsy may be forgone after endoscopic eradication of BE

20221202080000

Random histological sampling from the esophagogastric junction (EGJ) appears to hold low clinical relevance in patients who have undergone successful endoscopic eradication of all visible Barrett’s esophagus (BE), given that the incidence of intestinal metaplasia at the EGJ does not pose a higher risk of disease recurrence, according to a study.

P53 status identifies BE patients at risk of progression

20211112180000

Abnormal p53 immunohistochemical (IHC) findings may indicate a higher risk of progression in Barrett’s oesophagus (BE) patients, a new study has found.

Gonadotrophic hormones hold clue to Barrett’s oesophagus, oesophageal adenocarcinoma risk

20201208060000

Elevated predicted levels of follicle-stimulating and luteinizing hormones are associated with a lower risk of Barrett’s oesophagus (BE), oesophageal adenocarcinoma (EAC), according to the results of a Mendelian randomization analysis.

Transnasal capsule endoscope does not disappoint in Barret’s oesophagus screening

Jairia Dela Cruz, 20190228110000

A single use trasnasal endoscope, named EG Scan, is safe and highly accurate for detecting Barret’s oesophagus, with the sensitivity and specificity being higher than 90 percent, as compared with conventional esophagogastroduodenoscopy, according to a study.

GP symposium 2019: Updates on the Use of Probiotics in Clinical Practice

Dr. Gwee Kok Ann, Dr. Warren Lee, Dr. Mark Tang, Dr. Lim Sanghyun, 24 Apr 2019

Modulation of gut microbiota with probiotics has been studied in a wide range of clinical settings, in the hope of achieving health benefits in the host. Under the auspices of the Asian GI Faculty, four experts discussed the role of probiotics in clinical practice at the recent IMPACT (Improving Medical Practice through Advancement in Clinical Treatment) GP symposium in Singapore sponsored by DCH Auriga.

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.

Updates in the Management of Gastric Cancer

Prof Yasuhiro Kodera, Prof Winnie Yeo, 23 Jul 2019

Globally, gastric cancer is the third leading cause of cancer death.¹ Its primary treatment is gastrectomy with adjuvant chemotherapy or chemoradiotherapy to improve survival. Although neoadjuvant chemotherapy or adjuvant chemoradiation is preferred in Western countries, postoperative adjuvant chemotherapy is still the mainstream therapeutic strategy in Asia.² At a recent symposium in Hong Kong, experts discussed updates in the treatment and management of gastric cancer, with a focus on the use of S-1 (TS-ONE^®; Taiho Pharma Singapore), a combination of tegafur, gimeracil, and oteracil potassium.